Trypsin mutants for structure-based drug design: Expression, refolding and crystallisation

Biological Chemistry

Volumn 383, Issue 7-8, 2002, Pages 1309-1314

  Rauh, Daniel ^a   Reyda, Sabine ^a   Klebe, Gerhard ^a   Stubbs, Milton T ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Crystal structure; Factor Xa; Inhibitor; Structural genomics

Indexed keywords

BENZAMIDINE; BLOOD CLOTTING FACTOR 10A; CYCLOHEPTANE DERIVATIVE; CYSTEINE PROTEINASE INHIBITOR; DRUG; LIGAND; MUTANT PROTEIN; PIPERIDINE DERIVATIVE; SERINE PROTEINASE; TRYPSIN;

ARTICLE; BINDING SITE; CATTLE; COMPUTER AIDED DESIGN; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME PURIFICATION; ENZYME STRUCTURE; FEASIBILITY STUDY; LIGAND BINDING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN INTERACTION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG ANTAGONISM; GENETICS; METHODOLOGY; MUTATION; PEPTIDE MAPPING; PROTEIN RENATURATION; STRUCTURE ACTIVITY RELATION;

BOS TAURUS; BOVINAE;

ANIMALS; BINDING SITES; CATTLE; CRYSTALLIZATION; DRUG DESIGN; FACTOR XA; MUTATION; PEPTIDE MAPPING; PROTEIN RENATURATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPSIN;

EID: 0036661079     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2002.148     Document Type: Article

References (38)

1. Brandstetter, H., Kuhne, A., Bode, W., Huber, R., von der Saal, W., Wirthensohn, K. and Engh, R. A. (1996). X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J. Biol. Chem. 271, 29988-29992.
2. Brünger, A. (1992). X-PLOR (Version 3.1). A System for X-ray Crystallography and NMR (New Haven, CT, USA: Yale University Press).
3. Davie, E. W., Fujikawa, K. and Kisiel, W. (1991). The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30, 10363-10370.
4. Hedstrom, L., Lin, T Y. and Fast, W. (1996). Hydrophobic interactions control zymogen activation in the trypsin family of serine proteases. Biochemistry 35, 4515-4523.
5. Heinemann, U., Frevert, J., Hofmann, K., Illing, G., Maurer, C., Oschkinat, H. and Saenger, W. (2000). An integrated approach to structural genomics. Prog. Biophys. Mol. Biol. 73, 347-362.
6. Heinemann, U., Illing, G. and Oschkinat, H. (2001). High-throughput three-dimensional protein structure determination. Curr. Opin. Biotechnol. 12, 348-354.
7. Hirsh, J. and Weitz, J. I. (1999). New antithrombotic agents. Lancet 353, 1431-1436.
8. Hol, W. G. (2000). Structural genomics for science and society. Nature Struct. Biol. 7 (Suppl.), 964-966.
9. Jones, T. A., Zou, J. Y., Cowan, S. W. and Kjeldgaard. (1991). Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119.
10. Light, A., Duda, C. T, Odorzynski, T W. and Moore, W. G. (1986). Refolding of serine proteinases. J. Cell. Biochem. 31, 19-26.
11. Mackman, R. L., Katz, B. A., Breitenbucher, J. G., Hui, H. C., Verner, E., Luong, C., Liu, L. and Sprengeler, P. A. (2001). Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator. J. Med. Chem. 44, 3856-3871.
12. Maignan, S., Guilloteau, J. R, Pouzieux, S., Choi-Sledeski, Y. M., Becker, M. R., Klein, S. I., Ewing, W. R., Pauls, H. W., Spada, A. P. and Mikol, V. (2000). Crystal structures of human factor Xa complexed with potent inhibitors. J. Med. Chem. 43, 3226-3232.
13. Mole, J. E. and Horton, H. R. (1973). Kinetics of papain-catalyzed hydrolysis of N-benzoyl-L-arginine-p-nitroanilide. Biochemistry 12, 816-822.
14. Mozhaev, V. V. and Martinek, K. (1981). The influence of effectors on the refolding (reactivation) of immobilized trypsin. Eur. J. Biochem. 115,143-147.
15. Nar, H., Bauer, M., Schmid, A., Stassen, J. M., Wienen, W., Priepke, H. W., Kauffmann, I. K., Ries, U. J. and Hauel, N. H. (2001). Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa. blood coagulation inhibitors Structure 9, 29-37.
16. Nienaber, V. L., Davidson, D., Edalji, R., Giranda, V. L., Klinghofer, V., Henkin, J., Magdalinos, R, Mantei, R., Merrick, S., Severin, J. M. et al. (2000). Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Structure Fold. Des. 8, 553-563.
17. Odorzynski, T W. and Light, A. (1979). Refolding of the mixed disulfide of bovine trypsinogen and glutathione. J. Biol. Chem. 254, 4291 -4295.
18. Otwinowski, Z. and Minor, W. (1997). Processing of X-ray Diffraction Data Collected in Oscillation Mode. In: Macromolecular Crystallography, part A, Methods in Enzymology Vol. 276, C.W. Carter, Jr., and R.M. Sweet, eds. (New York, USA: Academic Press), pp. 307-326.
19. Padmanabhan, K., Padmanabhan, K. R, Tulinsky, A., Park, C. H., Bode, W., Huber, R., Blankenship, D. T, Cardin, A. D. and Kisiel, W. (1993). Structure of human des(l-45) factor Xa at 2.2 Å resolution. J. Mol. Biol. 232, 947-966.
20. Peterson, F C., Gordon, N. C. and Gettins, P. G. (2001). High-level bacterial expression and 15N-alanine-labeling of bovine trypsin. Application to the study of trypsin-inhibitor complexes and trypsinogen activation by NMR spectroscopy. Biochemistry 40, 6275-6283.
21. Phillips, G. B., Buckman, B. O., Davey, D. D., Eagen, K. A., Guilford, W. J., Hinchman, J., Ho, E., Koovakkat, S., Liang, A., Light, D. R. et al. (1998). Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy ]pyridin-4-yl]-N-methylglycine(ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. J. Med. Chem. 41, 3557-3562.
22. Pinto, D. J., Orwat, M. J., Wang, S., Fevig, J. M., Quan, M. L., Amparo, E., Cacciola, J., Rossi, K. A., Alexander, R. S., Small-wood, A. M. et al. (2001). Discovery of 1-[3-(aminomethyl)-phenyll -N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyll-4-yl]3-(trifluoromethyl) -1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 44, 566-578.
23. Renatus, M., Bode, W., Huber, R., Stürzebecher, J., Prasa, D., Fischer, S., Kohnert, U. and Stubbs, M. T (1997). Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors. J. Biol. Chem. 272, 21713-21719.
24. Renatus, M., Bode, W., Huber, R., Stürzebecher, J. and Stubbs, M. T. (1998). Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. J. Med. Chem. 41, 5445-5456.
25. Rudolph, R., Böhm, G., Lilie, H. and Jaenicke, R. (1996). Folding proteins. Practical Approach Series (Oxford, UK: Oxford University Press).
26. Sanchez, R., Pieper, U., Melo, F., Eswar, N., Marti-Renom, M. A., Madhusudhan, M. S., Mirkovic, N. and Sali, A. (2000). Protein structure modeling for structural genomics. Nature Struct. Biol. 7 (Suppl.), 986-990.
27. Schafferhans, A. and Klebe, G. (2001). Docking ligands onto binding site representations derived from proteins built by homology modelling. J. Mol. Biol. 307, 407-427.
28. Shaw, K. J., Guilford, W. J., Dallas, J. L., Koovakkaat, S. K., McCarrick, M. A., Liang, A., Light, D. R. and Morrissey, M. M. (1998). (Z,Z)-2,7-Bis(4-amidinobenzylidene)cycloheptan-1-one: identification of a highly active inhibitor of blood coagulation factor Xa. J. Med. Chem. 41, 3551-3556.
29. Sperl, S., Bergner, A., Stürzebecher, J., Magdolen, V, Bode, W. and Moroder, L. (2000a). Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies. Biol. Chem. 381, 321 -329.
30. Sperl, S., Jacob, U., Arroyo de Prada, N., Stürzebecher, J., Wilhelm, O. G., Bode, W., Magdolen, V., Huber, R. and Moroder, L. (2000b). (4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. Proc. Natl. Acad. Sci. USA 97, 5113-5118.
31. Stubbs, M. T. and Bode, W. (1993). A player of many parts: the spotlight falls on thrombin's structure. Thromb. Res. 69, 1-58.
32. Stubbs, M. T., Huber, R. and Bode, W. (1995). Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin. FEBS Lett. 375, 103-107.
33. Stubbs, M. T., Reyda, S., Dullweber, F., Möller, M., Klebe, G., Dorsch, D., Mederski, W. W. K. R. and Wurziger, H. (2002). pH-dependent binding modes observed in trypsin crystals - Lessons for structure-based drug design. ChemBioChem 3, 246-249.
34. Stürzebecher, J., Markwardt, F., Voigt, B., Wagner, G. and Walsmann, P. (1983). Cyclic amides of N alpha-arylsulfonylaminoacylated 4- amidinophenylalanine-tight binding inhibitors of thrombin. Thromb. Res. 29, 635-642.
35. Stürzebecher, J., Prasa, D., Hauptmann, J., Vieweg, H. and Wikstrom, P. (1997). Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J. Med. Chem. 40, 3091-3099.
36. Stürzebecher, J., Prasa, D., Wikstrom, R and Vieweg, H. (1995). Structure-activity relationships of inhibitors derived from 3-amidinophenylalanine. J. Enzyme Inhib. 9, 87-99.
37. Stürzebecher, J., Stürzebecher, U., Vieweg, H., Wagner, G., Hauptmann, J. and Markwardt, F. (1989). Synthetic inhibitors of bovine factor Xa and thrombin comparison of their anticoagulant efficiency. Thromb. Res. 54, 245-252.
38. Thornton, J. M., Todd, A. E., Milburn, D., Borkakoti, N. and Orengo, C. A. (2000). From structure to function: approaches and limitations. Nature Struct. Biol. 7 Suppl, 991-994.